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Abstract The most common sub-variant of papillary thyroid
carcinoma (PTC) is the so-called follicular variant (FVPTC),
which is a particularly problematic lesion and can be
challenging from a diagnostic viewpoint even in resected
lesions. Although fine needle aspiration cytology is very
useful in the diagnosis of PTC, its accuracy and utility would
be greatly facilitated by the development of specific markers
for PTC and its common variants. We used the recently
developed Applied Biosystems 1700 microarray system to
interrogate a series of 11 benign thyroid lesions and
conditions and 14 samples of PTC (six with classic
morphology and eight with follicular variant morphology).
TaqMan® reverse transcriptase-polymerase chain reaction
was used to validate the expression portfolios of 50 selected
transcripts. Our data corroborates potential biomarkers
previously identified in the literature, such as LGALS3,
S100A11, LYN, BAX, and cluster of differentiation 44
(CD44). However, we have also identified numerous tran-
scripts never previously implicated in thyroid carcinogenesis,
and many of which are not represented on other microarray
platforms. Diminished expression of metallothioneins fea-
tured strongly among these and suggests a possible role for
this family as tumour suppressors in PTC. Fifteen transcripts
were significantly associated with FVPTC morphology.
Surprisingly, these genes were associated with an extremely
narrow repertoire of functions, including the major histocom-
patibility complex and cathepsin families.
Keywords Papillarythyroidcarcinoma.Biomarker.
Follicularvariant.Microarray.TaqMan®PCR
Introduction
Papillary thyroid carcinoma (PTC) is the most common
endocrine malignancy and encompasses a variety of morpho-
logical/architectural variants,all ofwhichare characterizedby
a distinctive nuclear appearance. In recent years, PTC has
become an important paradigm of solid tumour molecular
pathogenesis principally arising from intensive investigation
prompted by the Chernobyl accident.
The discovery of ret rearrangements [12, 13, 35] and
their association with radiation [42] was followed by the
demonstration of the BRAF V600E mutation [21, 30]
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non-radiation exposed populations [22, 32]. In the past, our
group and others have noted an association between classic
morphology and the BRAF V600E mutation and between
variant morphology and ret rearrangements particularly ret/
PTC-3 [11, 39]. Similarly ret/PTC-3 appears to strongly
correlate with the solid/follicular variant seen commonly in
children exposed to the Chernobyl fallout [42]. Neverthe-
less, the utility of these genetic lesions to diagnostic
pathology and clinical practice has remained negligible.
Recently, gene expression microarray technology has been
used to attempt to identify clinically relevant biomarkers of
malignancy related to the thyroid [2, 6, 9, 10, 20, 28]. The
discovery of such a biomarker or panel of biomarkers allied
to the gold standard triage method of fine needle aspiration
cytology (FNAC) would represent a significant advancement
in the treatment of the solitary thyroid nodule.
An intriguing but commonly occurring variant of PTC is
known as follicular variant (FVPTC). This lesion, which by
definition retains the classic nuclear features of PTC, shows
no evidence of the architectural papillae. FVPTC may be a
controversial lesion due to interobserver variation in its
pathological diagnosis [25]. Further, the occurrence of
follicular patterned lesions with poorly or incompletely
developed nuclear features may occur, which are easily
dismissed as benign thyroid nodules. This has led to the
controversial designation “well-differentiated tumour of
uncertain malignant potential” for tumours of this type [45].
It is clear that this is a complex and contentious area, and
that further work needs to be done to ascertain the underlying
molecular biology of this particular variant. Recently, inroads
into elucidation of molecular pathways underpinning PTC
have been carried out using microarray studies. The overrid-
ing objective of these investigations was to identify clinically
useful biomarkers. However, the majority of these studies
have analysed PTC as though it were a homogenous singular
entity without deference in a detailed manner to sub-variants
and, in particular, the most common variant (FVPTC). The
identification of specific biomarkers of FVPTC and a deeper
understanding of its origins are clearly warranted.
The aim of this expression microarray study using a
novel microarray platform was twofold: to identify markers
that distinguish PTC from benign thyroid tissue and lesions
and, secondly, to identify potential markers and further
explore the molecular pathology of FVPTC.
Materials and methods
Patients and tissue samples
Tissue from 25 thyroid resections was collected prospec-
tively from patients undergoing partial or total thyroidecto-
my for a variety of reasons at St. James’s Hospital, Dublin.
The study had approval of the local ethics committee and
informed consent was obtained from each patient by the
clinical team before surgery. Small samples (<1 cm) were
divided and immediately snap-frozen in liquid nitrogen for
storage at −80°C until use. Histopathological examination
of formalin-fixed paraffin-embedded sections was per-
formed by two pathologists (SF and MT) for diagnostic
categorisation. Classification of neoplastic tissue was made
according to a recognised system [24]. The cohort
comprised 11 benign lesions or conditions including
follicular adenoma, nodular goitre, normal thyroid tissue,
and Graves’s thyroiditis. The remaining 14 samples were
diagnosed as PTC and comprised six classical morphology
PTC and eight FVPTC (see Table 1). Immediately before
RNA extraction, frozen sections were cut and stained to
confirm the presence of representative lesional tissue with
morphology corresponding to that noted in the diagnostic
formalin-fixed paraffin-embedded sections.
RNA isolation and characterization
Samples were ground in liquid nitrogen and homogenised
in RLT buffer (Qiagen, UK). RNAwas then extracted using
Table 1 Sample cohort
Identifier Diagnosis
N1 Normal thyroid tissue
N2 Normal thyroid tissue
N3 Lymphocytic thyroiditis
N4 Nodular hyperplasia
N5 Follicular adenoma
N6 Nodular hyperplasia with focal lymphocytic thyroiditis
N7 Nodular hyperplasia
N8 Follicular adenoma
N9 Nodular hyperplasia
N10 Follicular adenoma
N11 Grave’s thyroiditis
T1 Solid/FVPTC
T2 FVPTC
T3 PTC classic morphology
T4 FVPTC-oxyphil
T5 FVPTC
T6 FVPTC
T7 PTC classic morphology
T8 FVPTC
T9 PTC classic morphology
T10 FVPTC
T11 PTC classic morphology
T12 FVPTC
T13 PTC classic morphology
T14 PTC classic morphology
List of the 11 benign and 14 malignant lesions that were used in this
study.
FV follicular variant; PTC papillary thyroid carcinoma
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DNase digestion (Qiagen) according to the manufacturer’s
instructions. RNA quantity was determined using UV
spectrophotometry. RNA quality was assessed using the
RNA 6000 Nano LabChip® Kit in conjunction with the
Agilent 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany).
Microarray analysis
Applied Biosystems Human Genome Survey Arrays were
used to analyse the transcriptional profiles of thyroid RNA
samples in this study. Digoxigenin-UTP-labelled cRNAwas
generated and linearly amplified from 5 μg of total RNA
using Applied Biosystems Chemiluminescent RT-IVT
Labelling Kit v 2.0 using manufacturer’s protocol. 10 μg
of labelled cRNA were hybridized to each pre-hybed
microarray in a 1.5-ml volume at 55°C for 16 h. Array
hybridization and chemiluminescence detection were per-
formed using Applied Biosystems Chemiluminescence
Detection Kit following manufacturer’s protocol. Images
were collected for each microarray using the 1700 analyser.
Images were auto-gridded and the chemiluminescent
signals were quantified, corrected for background and spot,
and spatially normalized.
TaqMan® PCR validation
Sufficient RNA remained from 20 of the initial 25 samples
for TaqMan® polymerase chain reaction (PCR) validation
in a series of 50 targets. RNA was reverse transcribed using
a High Capacity cDNA Archive Kit (Applied Biosystems,
CA, USA). Primers and probes for TaqMan® PCR were
obtained by using Applied Biosystems’ pre-designed Taq-
Man® Gene Expression Assays. PCR was carried out using
an ABI PRISM 7900 Sequence Detection System (Applied
Biosystems). Analysis of relative gene expression data was
performed using the ΔΔCT method [23] with glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) as an endoge-
nous control/reference assay.
Statistical analysis
Microarrays were analysed using Spotfire DecisionSite™
for Functional Genomics (Spotfire AB, Goteborg, Sweden)
and R version 1.9.1, a free language and environment for
statistical computing and graphics (R Development Core
Team, 2004). Arrays were initially normalized, and genes
were deemed undetectable and, therefore, excluded from
final gene lists if they had a signal-to-noise ratio of less
than three (S/N<3) in greater than 18 of the 25 arrays.
An ANOVA test was used to generate p values for
statistical differences between groups. Their p values were
then adjusted for multiple comparisons using the technique
described by Benjamini and Yekutieli [3]. Genes were
deemed statistically different between groups if they had an
adjusted p<0.05 and an average fold-change difference of
greater than 2. Hierarchical clustering was performed based
on the statistically different genes to determine whether
samples grouped appropriately. Gene ontology analysis was
performed using an online database known as the Panther
classification system (http://www.pantherdb.org). Correla-
tions between microarray and TaqMan® expression data
were measured using the Pearson coefficient.
Results
Unsupervised clustering of all 25 samples demonstrated
clusteringintotwomajorgroups(datanotshown)comprising
the N group and the T group (see Table 1). There was no
tendency for FVPTC to cluster independently with classic
morphology PTC, confirming the close relationship of these
variants of PTC. To identify potential markers of malignancy,
ANOVA with false discovery rate correction was used to
compare the benign and malignant thyroid cohorts. A p value
cut-off of <0.05 and fold-change difference of ≥2 yielded
236 statistically significant probes. Of these, 172 corre-
sponded to fully annotated probes and are listed in Table 2.
Supervised hierarchical clustering was performed on the 25
arrays based on the 236 statistically significant probes to
determine whether the samples would segregate appropriately.
The resulting heat map can be observed in Fig. 1.B e n i g n
lesions and tumours clustered together with the exception of
one tumour sample that clustered with the benign group (T5).
A binomial statistics tool was used to compare classi-
fications of multiple clusters of lists to a reference list (i.e.
the complete human genome) to statistically determine
over- or under-representation of Panther classification
categories. Biological processes over-represented in the
up-regulated PTC cohort included tumour suppressor,
oncogenesis, DNA replication, cell cycle, and cell adhesion
(p<0.0001). Genes involved in homeostasis and other
homeostasis activities were highly over-represented in the
down-regulated cohort (p<0.000001).
ANOVA tests were used to determine which genes were
differentially regulated in the FVPTC cohort only. Fifteen
genes were identified, including cluster of differentiation 14
(CD14), CD74, CTSC, CTSH, CTSS, DPP6, ETHE1,
human leucocyte antigen A (HLA-A), HLA-DMA, HLA-
DPB1, HLA-DQB1, HLA-DRA, osteoclast stimulating
factor 1 (OSTF1), TDO2, and a previously uncharacterized
gene (noname).
Microarray results were validated using a reverse
transcription reaction followed by TaqMan® PCR for 50
gene targets. The ΔΔCT method [23] was used to analyse
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Gene Name Gene Symbol Adjusted
p value
1700 probe
ID
Genes up-regulated in malignant vs benign
Active BCR-related gene ABR 0.014482 154399
Adaptor-related protein complex 2, alpha 1 subunit AP2A1 0.0312 115368
Apoptosis, caspase activation inhibitor AVEN 0.030998 203738
BCL2-associated X protein BAX 0.009782 146510
BH3 interacting domain death agonist BID 0.021424 131216
Brain abundant, membrane attached signal protein 1 BASP1 0.024214 198318
Brain acyl-CoA hydrolase BACH 0.014566 133876
Bromodomain adjacent to zinc finger domain, 1A BAZ1A 0.03538 209809
Calcium/calmodulin-dependent protein kinase I CAMK1 0.041887 157712
Cathepsin S CTSS 0.046544 105790
CD44 antigen (homing function and Indian blood group system) CD44 0.044181 133604
Chemokine (C-X-C motif) ligand 16 CXCL16 0.043234 199059
Chromosome 1 open reading frame 38 C1orf38 0.049072 202924
CLIP-170-related protein CLIPR-59 0.023629 102205
Docking protein 1, 62 kDa (downstream of tyrosine kinase 1) DOK1 0.041898 204989
Epidermodysplasia verruciformis 1 EVER1 0.003348 175569
FXYD domain containing ion transport regulator 5 FXYD5 0.01444 154607
FXYD domain containing ion transport regulator 5 FXYD5 0.023629 112771
Galactose-4-epimerase, UDP GALE 0.047363 141143
Genethonin 1 GENX-3414 0.016836 124360
Hypothetical gene BC008967 BC008967 0.015683 108526
Hypothetical protein FLJ10849 FLJ10849 0.013822 224983
Hypothetical protein FLJ22531 FLJ22531 0.024391 145918
Hypothetical protein MGC4607 MGC4607 0.006507 211836
Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor ICAM1 0.028746 109070
Jun dimerization protein p21SNFT SNFT 0.043301 144215
Lectin, galactoside-binding, soluble, 3 (galectin 3) LGALS3 0.034491 179836
Major vault protein MVP 0.0312 212354
Matrix metalloproteinase 14 (membrane-inserted) MMP14 0.038682 152076
Milk fat globule-EGF factor 8 protein MFGE8 0.02392 144588
Mst3 and SOK1-related kinase MST4 0.042028 112198
neuronal cell adhesion molecule NRCAM 0.011178 106462
Phospholipase D3 PLD3 0.034491 143388
Promyelocytic leukemia PML 0.016018 217558
Protein inhibitor of activated STAT protein PIASy PIASY 0.00536 153434
Protein tyrosine phosphatase, receptor type, E PTPRE 0.048653 221568
Rho GDP dissociation inhibitor (GDI) beta ARHGDIB 0.043853 143589
S100 calcium binding protein A11 (calgizzarin) S100A11 0.019933 145550
Similar to rat tricarboxylate carrier-like protein BA108L7.2 0.025387 179870
SP110 nuclear body protein SP110 0.0312 113484
Stimulated by retinoic acid gene 6 FLJ12541 0.043234 193986
Syndecan 3 (N-syndecan) SDC3 0.048804 143980
Tax interaction protein 1 TIP-1 0.006673 119665
TBC1 domain family, member 2 TBC1D2 0.029907 205982
Tenascin C (hexabrachion) TNC 0.032355 143831
Thymosin, beta 4, Y chromosome TMSB4Y 0.040937 193911
Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity,
collagenase inhibitor)
TIMP1 0.032306 134692
Topoisomerase (DNA) II alpha 170 kDa TOP2A 0.040937 135302
Transforming growth factor, beta 1 TGFB1 0.016836 170749
Transgelin 2 TAGLN2 0.031971 172296
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein,
eta polypeptide
YWHAH 0.039009 188379
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN 0.016175 194134
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Gene Name Gene Symbol Adjusted
p value
1700 probe
ID
Genes down-regulated in malignant vs benign
Aldehyde oxidase 1 AOX1 0.003227 106573
Ankyrin 2, neuronal ANK2 0.035357 155780
Aspartate beta-hydroxylase ASPH 0.002064 221656
Aspartate beta-hydroxylase ASPH 0.019666 114180
ATPase, Cu++ transporting, beta polypeptide ATP7B 0.044511 198852
Brain-specific protein p25 alpha p25 0.023629 120622
Casein kinase LOC149420 0.022382 149347
Cellular retinoic acid binding protein 1 CRABP1 0.008315 100295
Centromere protein J CENPJ 0.0312 164563
Ceroid-lipofuscinosis, neuronal 5 CLN5 0.011021 205999
Chloride channel Kb CLCNKB 0.040418 176266
Chondroitin beta1,4 N-acetylgalactosaminyltransferase ChGn 0.013148 101140
Chromosome 11 open reading frame 8 C11orf8 0.001977 174025
Chromosome 11 open reading frame 8 C11orf8 0.004148 108279
Chromosome 21 open reading frame 4 C21orf4 0.0042 156895
Clusterin-like 1 (retinal) CLUL1 0.019631 186062
Component of oligomeric golgi complex 3 COG3 0.003664 129212
Coxsackie virus and adenovirus receptor CXADR 0.004648 108284
Crystallin, alpha B CRYAB 0.030418 190274
Cytosolic sialic acid 9-O-acetylesterase homolog CSE-C 0.040993 213856
Dicarbonyl/L-xylulose reductase DCXR 0.001977 103350
DnaJ (Hsp40) homolog, subfamily B, member 4 DNAJB4 0.043853 103618
ERO1-like beta (S. cerevisiae) ERO1LB 0.013962 207998
Extracellular link domain containing 1 XLKD1 0.039738 195865
Family with sequence similarity 13, member A1 FAM13A1 0.019631 116936
Fatty acid binding protein 4, adipocyte FABP4 0.014832 150137
Fc fragment of IgG binding protein FCGBP 0.001965 118361
Fibroblast growth factor receptor 2 FGFR2 0.0042 110548
FLJ35740 protein FLJ35740 0.020224 101102
Friedreich ataxia region gene X123 X123 0.032602 133505
Glutamate-ammonia ligase (glutamine synthase) GLUL 0.014649 175147
Glycine amidinotransferase (L-arginine/glycine amidinotransferase) GATM 0.013962 111904
Glycoprotein M6A GPM6A 0.011739 215326
Growth hormone receptor GHR 0.017721 190306
HLA complex group 4 HCG4 0.025807 191199
Hypothetical protein BC009561 LOC119710 0.003227 211319
Hypothetical protein BC019238 LOC120379 0.013438 201200
Hypothetical protein FLJ13204 FLJ13204 0.003227 145066
Hypothetical protein FLJ13842 FLJ13842 0.016448 208504
Hypothetical protein FLJ14054 FLJ14054 0.049072 202017
Hypothetical protein FLJ20154 FLJ20154 0.014428 143310
Hypothetical protein FLJ20513 FLJ20513 0.019493 154130
Hypothetical protein FLJ32110 FLJ32110 0.015507 229492
Hypothetical protein FLJ32343 FLJ32343 0.012208 116902
Hypothetical protein FLJ33516 FLJ33516 0.03965 224600
Hypothetical protein FLJ37549 FLJ37549 0.001956 218577
Hypothetical protein FLJ39378 FLJ39378 0.005853 163223
Hypothetical protein FLJ40021 FLJ40021 0.023629 174198
Hypothetical protein LOC134285 LOC134285 0.018694 163671
Hypothetical protein MGC10946 MGC10946 0.022382 195982
Hypothetical protein MGC14425 MGC14425 0.015445 161569
Hypothetical protein MGC17299 MGC17299 0.026062 168452
Hypothetical protein MGC17943 MGC17943 0.0042 147296
Hypothetical protein MGC23980 MGC23980 0.018694 224619
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Gene Name Gene Symbol Adjusted
p value
1700 probe
ID
Hypothetical protein MGC24047 MGC24047 0.001956 138122
Hypothetical protein MGC33607 MGC33607 0.033547 100645
Ionized calcium binding adapter molecule 2 IBA2 0.0042 179489
KIAA0390 gene product KIAA0390 0.014832 119936
KIAA0703 gene product KIAA0703 0.032602 146652
Lectin, mannose-binding, 1 LMAN1 0.031092 179632
Leiomodin 1 (smooth muscle) LMOD1 0.022352 120404
Likely ortholog of rat SNF1/AMP-activated protein kinase SNARK 0.044605 157942
LIM domain kinase 2 LIMK2 0.002409 151439
Low density lipoprotein-related protein 1B (deleted in tumors) LRP1B 0.00536 209464
Low density lipoprotein-related protein 2 LRP2 0.040937 114919
Matrilin 2 MATN2 0.0042 167316
Metallothionein 1A (functional) MT1A 0.013822 204773
Metallothionein 1A (functional)|metallothionein 1E
(functional)|metallothionein 1K| metallothionein 2A
MT1A|MT2A|
MT1E|MT1K
0.027037 146368
Metallothionein 1A (functional)|metallothionein 1E
(functional)|metallothionein 2A| metallothionein 1K
MT1A|MT2A|
MT1K|MT1E
0.043841 182305
Metallothionein 1A (functional)|metallothionein 2A|metallothionein 1K|
metallothionein 1E (functional)
MT1A|MT1K|
MT1E|MT2A
0.011739 223856
Metallothionein 1B (functional) MT1B 0.019631 174119
Metallothionein 1F (functional) MT1F 0.024726 144569
Metallothionein 1G MT1G 0.0192 164525
Metallothionein 1G MT1G 0.03965 171539
Metallothionein 1J MT1J 0.008315 227956
Metallothionein 1X MT1X 0.008335 119685
Metallothionein 1X MT1X 0.010748 173072
Metallothionein IV MT4 0.007447 223241
Methionine adenosyltransferase II, alpha MAT2A 0.014428 158350
Mitogen-activated protein kinase 4 MAPK4 0.042306 131252
Myc-induced nuclear antigen, 53 kDa MINA53 0.011959 130284
NIMA (never in mitosis gene a)- related kinase 11 NEK11 0.001965 194628
Otospiralin LOC150677 0.018694 182360
PDZ/coiled-coil domain binding partner for the rho-family GTPase TC10 PIST 0.013822 103651
Phospholipase A2 receptor 1, 180 kDa PLA2R1 0.004029 134379
Phospholipase C-like 1 PLCL1 0.022657 206894
Phosphotidylinositol transfer protein, beta PITPNB 0.014428 122698
Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 PKHD1L1 0.0042 199896
Polymerase (DNA directed) iota POLI 0.003227 167492
Potassium channel, subfamily K, member 9 KCNK9 0.000849 108648
Potassium channel-interacting protein 4 KCNIP4 0.011447 147058
Potassium inwardly-rectifying channel, subfamily J, member 13 KCNJ13 0.008972 124187
pp21 Homolog LOC51186 0.004326 127636
Pre-B cell leukemia transcription factor 4 PBX4 0.030311 199118
Protein kinase, cAMP-dependent, catalytic, beta PRKACB 0.023863 198878
Protein phosphatase 4, regulatory subunit 2|hypothetical protein LOC151987 PPP4R2|LOC151987 0.011338 200919
RAB23, member RAS oncogene family RAB23 0.000659 122394
Ras association (RalGDS/AF-6) domain family 6 RASSF6 0.048804 119072
Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein) SGCD 0.011178 120415
Serum deprivation response (phosphatidylserine binding protein) SDPR 0.011021 156433
SH3 and multiple ankyrin repeat domains 2 SHANK2 0.043996 193906
Solute carrier family 26, member 7 SLC26A7 0.0042 225067
Solute carrier family 26, member 7 SLC26A7 0.005853 213530
Solute carrier family 5 (iodide transporter), member 8 SLC5A8 0.031284 231731
SPARC related modular calcium binding 2 SMOC2 0.021505 135930
Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan) SDC2 0.001258 209676
Syntaxin 12 STX12 0.01117 199949
254 Virchows Arch (2007) 450:249–260relative gene expression data. GAPDH was used as an
endogenous control, and T12 was chosen as an arbitrary
calibrator sample. Gene expression profiles for TaqMan®
PCR were plotted in conjunction with those for microarray
results in Fig. 2. Pearson co-efficient was used to directly
compare data from microarray analysis and TaqMan® RT-
PCR. Table 3 depicts genes differentially expressed in both
benign vs malignant and FVPTC vs classic morphology
PTC.
Discussion
The primary aim of this study was to generate an overview
of molecular markers of malignancy in PTC with a view to
identifying discriminators between common sub-types
(classic PTC and FVPTC), using genome-wide expression
microarray technology validated by TaqMan® RT-PCR. To
this end, lesions that were well characterized histologically
were selected.
The application of microarray analysis designed to
identify transcripts strongly associated with each group of
interest yielded a gene list of 173 genes that were
differentially expressed between cohorts. Significant
down-regulation of Coxsackie virus receptor was recorded
in the malignant cohort of thyroid lesions. The Coxsack-
ievirus B and adenovirus receptor (CAR) plays a dual role
as a homotypic junctional adhesion protein and as a viral
receptor. It is biologically plausible that altered expression
may impact on the morphology peculiar to PTC given its
association with cellular adhesion. CAR has been shown to
be differentially expressed in various human adenocarcino-
mas, and differential expression may represent a new factor
in thyroid tumourigenesisigenesis [27].
Rab 23 expression was also down regulated in the
malignant cohort. The Rab small G protein family is
composed of approximately 40 members. Many of them
are ubiquitous and are expressed and participate in transport
processes, such as endocytosis and exocytosis [26]. Other
gene targets demonstrating significant down-regulation in
the malignant group were syndecans 2 and 3. Syndecans
are transmembrane proteoglycans expressed on adherent
cells. Changes in syndecan expression have been postulated
to influence cell adhesion, migration, and the structure of
focal contacts and the cytoskeleton [8].
The abundance of metallothionein genes in the cohort of
genes down-regulated in PTC is interesting partly because
of the sheer number of isoforms detected (Table 2). There
have been many studies showing increased metallothionein
expression in a plethora of cancer types but few showing
decreased expression [4, 7, 33]. Although previous micro-
array experiments showed metallothionein genes to be
down-regulated in thyroid tumours to a certain extent [2,
9, 16], none have detected so many as the current study.
Apart from microarray experiments, there has been little
reported in the literature regarding metallothioneins in
thyroid cancer. An early report by Nartey et al. [31]
showed metallothioneins to be expressed actively in certain
human thyroid neoplastic tissues but not in normal thyroid
tissue, which would seem to contradict the current authors’
findings. In contrast to this, a later immunohistochemical
study showed an absence of metallothionein expression in
13 of 20 PTCs [36]. Interestingly, in three of the seven
positive PTCs, metallothionein positivity was restricted to
areas of follicular differentiation. In one of the only recent
studies, Huang et al. [17] followed up their initial micro-
array experiment by showing that MT1G is down regulated
in PTC via hypermethylation. The biological significance
Table 2 (continued)
Gene Name Gene Symbol Adjusted
p value
1700 probe
ID
T-box 22 TBX22 0.024297 177517
Thioredoxin-like, 32 kDa TXNL 0.001102 192552
Thyroid stimulating hormone receptor TSHR 0.02176 108606
Tissue inhibitor of metalloproteinase 4 TIMP4 0.023629 184795
Trefoil factor 3 (intestinal) TFF3 0.004648 114445
Trefoil factor 3 (intestinal) TFF3 0.014428 100949
UDP-N-acetyl-alpha-D-galactosamine/polypeptide
N-acetylgalactosaminyltransferase 9 (GalNAc-T9)
GALNT9 0.031284 161042
WEE1 homolog (S. pombe) WEE1 0.024101 123533
WW domain containing oxidoreductase WWOX 0.012208 224298
WW domain containing oxidoreductase WWOX 0.024101 135080
Zinc finger protein 258 ZNF258 0.013962 225961
Zinc finger protein 36, C3H type-like 2 ZFP36L2 0.018837 210469
Two-tail ANOVA with p value correction yielded 173 probes (52 up-, 121 down-regulated in PTC) significantly different (p<0.05) between the
malignant and benign thyroid tissues.
Virchows Arch (2007) 450:249–260 255of low metallothionein expression in thyroid tumours is
therefore still poorly understood; however, it is interesting
to speculate that metallothioneins may have roles as tumour
suppressors in thyroid carcinoma.
Many genes identified, such as LGALS3 [9, 16, 20], LYN
[46], TFF3 [2, 9, 16], CRABP1 [9, 16], BAX [2], MAPK4
[28], CD44 [16], TIMP1 [20], FGFR2 [9], and S100A11
[20, 40], have been previously reported in both microarray
and conventional experiments in thyroid cancer. The data
generated in this study corroborates the importance of
several biological processes in the progression of thyroid
neoplasia. For example, S100A11 expression was up
regulated in the PTC cohort compared with benign lesions,
paralleling the increased protein expression of this gene
target identified at the protein level using immunohisto-
chemistry [29]. S100A11 has also been suggested as a
biomarker of malignancy in the context of colorectal
carcinoma as long ago as 1995 [41].
Correlation of highlighted features with the current state
of knowledge of the molecular pathology of thyroid
neoplasia goes some way towards providing an external
validation of the data obtained from the AB1700 system.
However, additional validation using TaqMan® RT-PCR
was performed.
In general, microarray and TaqMan® data correlated well
with approx. 80% of comparisons having p<0.05. Candi-
date genes were selected contingent on results identified as
over-represented biological processes (oncogenesis, cell
cycling, DNA replication, and homeostasis) using the
Panther binomial statistics tool as opposed to the more
traditional method of selecting the most highly disregulated
genes. This may account for the poor correlation observed
with certain genes. Some genes, such as TFF3 and FGFR2,
had excellent correlation between microarray and TaqMan®
results, whereas others, such as BAX and TSHR, showed
poor correlation despite previous studies implicating them
Fig. 1 Hierarchical clustering
of samples. This heat map
shows the clustering of the 25
samples based on the 236 probes
found to be differentially regu-
lated in benign vs malignant
thyroid tissue. Clustering was
performed using the unweighted
pair group method with arith-
metic mean, with Euclidian dis-
tance as the similarity measure.
Average value was used as the
ordering function
256 Virchows Arch (2007) 450:249–260in thyroid cancer [15, 38]. Where there was discordance in
the data, it could be accounted for by differences in the
sequences targeted by the TaqMan® target sequences and
the microarray probe. In those cases, the array and pre-
designed TaqMan assays interrogated different exons or
alternative splice variants. This finding highlights the
importance of matching the targets to be validated from
microarray data sets.
Analysis of differentially expressed transcripts in the
FVPTC revealed many transcripts showing similar expres-
sion level patterns in both FVPTC and classic morphology
PTC. Examples of these transcripts are included in Table 2.
In addition, somewhat surprisingly, unsupervised clustering
of all samples showed no tendency for FVPTC to cluster
independently of classic morphology PTC, emphasizing the
very close relationship of these PTC variants (data not
shown). However, analysis of differentially expressed genes
in FVPTC exclusive of those identified in classic morphol-
ogy PTC revealed 15 genes exhibiting differential expres-
sion in FVPTC compared with benign lesions and
conditions outwith of classic morphology PTC. These
genes displayed a narrow gamut of function represented
by the transcripts involved (Table 3). TaqMan® RT-PCR
was performed for all of these targets to confirm the array
findings and correlation with the array data was strong (see
Table 3).
Aberrant expression of two major groups of transcripts
was noted in FVPTC. Relatively increased expression of
class 1 major histocompatibility complex (MHC) genes
(HLA-A) and aberrant expression of class 2 MHC genes
(HLA-DMA, HLA-DPB-1, HLA-DQB-1, HLA DRA) and
associated genes (e.g. CD74 represents the invariant
membrane bound moiety of class II HLA molecules and
regulates the biology and functions of MHC class II
molecules and CD14 is a surface marker of monocytes/
macrophages) were the most significant findings. Addition-
ally, relatively up-regulated expression of members of the
cathepsin family (cathepsin C, cathepsin H, cathepsin S,
and TDO2) was striking in the FVPTC group. HLA
expression is generally associated with immune functions
Fig. 2 TaqMan® PCR validation of microarray experiments. Profile charts of gene expression levels comparing results obtained by microarray
analysis (n=25) to TaqMan® PCR analysis (n=20) for six genes. Plots for those genes with multiple probes are also displayed where appropriate
Virchows Arch (2007) 450:249–260 257such as T cell interaction and antigen presentation. The
presence of prominent HLA transcript expression, especial-
ly among class 2 in FVPTC, is intriguing. One potential
cause of this was that tumour-infiltrating leucocytes were
responsible for this finding. However, haematoxylin–eosin
(H&E)-stained slides of each case were reviewed to
specifically identify the degree of tumour infiltration by
leucocytes. Although a mild lymphocytic infiltrate was
noted in some cases, there was no apparent over represen-
tation of lymphocytes in the follicular variant compared to
benign lesions and classic morphology PTC. This raises the
clear possibility that the findings represent aberrant in-
creased expression of class 2 HLA transcripts by the
epithelium of FVPTC. This is an unexpected finding, as
over-expression of MHC class 2 molecules would be
expected to increase tumour immunogenicity. A similar
aberrant expression of HLA transcripts has been recently
described in ovarian neoplasms [34]. Rangel et al. [34]
concluded over-expression of HLA-DRA might represent a
novel biomarker for malignancy, and this also seems
biologically plausible in the FVPTC setting. A recent paper
has also described HLA-DRA expression in ret/PTC-
activated papillary thyroid carcinoma but not in surround-
ing normal thyroid follicles [19]. Yu et al. [47] showed
discordant expression of (CD74Ii) and HLA-DR in Hashi-
moto thyroiditis, an autoimmune condition associated with
increased incidence of PTC and sharing molecular features
such as ret/PTC expression [18, 37]. Hwang et al. [19] have
drawn attention to aberrant expression of HLA-DRA in ret/
PTC-activated PTC. Expression of HLA-DRA may in some
way explain the propensity for PTC to metastasize to lymph
nodes and often apparently reside there without markedly
worsening prognosis.
Cathepsins C (dipeptidyl-peptidase I), H, and S showed
up-regulation in FVPTC compared to benign lesions.
Cathepsins are a family of proteases that play an important
role in protein degradation. They are key players in the
proliferative, invasive, and metastatic potential of malignant
tumour cells. Their expression in the relatively biologically
indolent FVPTC is intriguing, and it remains possible that
cathepsins have cellular roles outside of those involved in
invasion and dissemination of tumour cells as indeed has
been suggested by others [43]. For example, cathepsin L
has recently been shown to play a role in nuclear
transcriptional activation, and cathepsins are now recog-
nized to play a role in MHC class II antigen presentation
[44]. OSTF1 has no defined role in carcinogenesis,
although outside of its role in ossification, it is also known
to have roles in signal transduction and protein binding,
which may be relevant to carcinogenesis and, particularly,
FVPTC. A recent paper highlights the role of bone
mineralization proteins including osteopontin and osteoclast
stimulating factors as potential biomarkers of malignant
tumours in general [1]. Indeed, in addition to elevated
OSTF1 expression, increased expression of osteopontin
was seen in PTC (data not shown); however, in our data,
osteopontin does not appear to be specifically up-regulated
Table 3 Correlation between TaqMan® and microarray data
Gene Pearson’s r coefficient two-tailed p
Genes differentially expressed in FVPTC vs classic PTC
CD14 0.83 <0.0001
CD74
a 0.87 <0.0001
0.74 0.0002
CTSC 0.53 0.0170
CTSH 0.71 0.0005
CTSS 0.62 0.0037
DPP6 0.76 0.0001
ETHE1 0.30 0.2008
HLA-A 0.77 <0.0001
HLA-DMA 0.75 0.0001
HLA-DPB1 0.96 <0.0001
HLA-DQB1
a 0.70 0.0006
0.63 0.0031
HLA-DRA 0.82 <0.0001
NONAME −0.02 0.9323
OSTF1 0.15 0.5171
TDO2 0.68 0.0009
Genes differentially expressed in benign vs malignant
BAX 0.20 0.3997
CAMK1 0.17 0.4771
CD44 0.57 0.0094
CTSS 0.62 0.0037
CXADR 0.36 0.1152
FGFR2 0.84 <0.0001
GALE 0.54 0.0138
ICAM1 0.62 0.0038
LYN 0.45 0.0483
MAPK4 0.76 <0.0001
MMP14 0.36 0.1175
MT1F 0.92 <0.0001
MT1K
a 0.68 0.0011
0.69 0.0007
0.70 0.0006
MT1X
a 0.88 <0.0001
0.88 <0.0001
RAB23 0.70 0.0006
S100A11 0.61 0.0041
SDC2 0.34 0.1415
SDC3 0.57 0.0087
TFF3
a 0.97 <0.0001
0.96 <0.0001
TGFB1 0.56 0.0098
TIMP1 0.73 0.0003
TIMP4 0.80 <0.0001
TOP2A 0.07 0.7769
TSHR 0.18 0.4440
Gene expression profiles for TaqMan® PCR and microarray results
were compared using the Pearson coefficient.
aGenes have more than one probe ID on microarray
258 Virchows Arch (2007) 450:249–260in FVPTC, and this finding has also been noted by other
researchers [14]. In any case, osteopontin is known to be a
downstream effector of ret/PTC [5] and mutated BRAF
[14], where it acts in association with CD44, another
transcript showing increased expression in both classic
morphology PTC and FVPTC.
A particular focus of this study was to compare tran-
scriptome profiles for PTCs with classic morphology and
FVPTC given the propensity for FVPTC lesions to prove
problematic from a diagnostic perspective. Although the
study confirms the close relationship between the two most
common variants of PTC, a narrow portfolio of genes and, in
particular, gene functions was elucidated in the FVPTC
cohort. The targets identified are easily amenable to analysis
by more established techniques such as TaqMan® RT-PCR,
with associated potential as additional markers for application
in the FNAC setting. Clearly, the potential biomarkers
identified in this study will require prospective evaluation in
the context ofrealclinicaldiagnosticsituationsinthe futureto
consolidate their merit as adjunctive tests in the diagnostic
setting and to validate their altered expression states in the
pathobiology of PTC development.
Acknowledgement Dr. Smyth and Dr. Finn contributed equally to
this study.
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